RNA Sequencing Analysis of Patients with Chronic Hepatitis B Treated Using PEGylated Interferon
Shao-Long Chen,Yao-Jie Shen,Guo-Zhi Chen
DOI: https://doi.org/10.2147/ijgm.s474284
IF: 2.145
2024-10-01
International Journal of General Medicine
Abstract:Shao-Long Chen, 1 Yao-Jie Shen, 2 Guo-Zhi Chen 1 1 Department of Infectious Disease Control and Prevention, Yueqing Center for Disease Control and Prevention, Wenzhou, 325600, People's Republic of China; 2 Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, 200040, People's Republic of China Correspondence: Shao-Long Chen, Yueqing Center for Disease Control and Prevention, Wenzhou, 325600, People's Republic of China, Email Purpose: Worldwide, chronic hepatitis B virus (CHB) infection is a public health concern, ultimately leading to liver cirrhosis and hepatocellular carcinoma. Currently, patients with CHB can be treated using polyethylene glycol (PEG)ylated interferon (PEG-IFN) antiviral therapy, which has both immune modulatory and antiviral properties. This study aimed to reveal the mechanism underlying the effect of PEG-IFN therapy, to rationally optimize this therapeutic option. Patients and Methods: Ten patients with CHB who were positive for the hepatitis B virus e antigen (HBeAg) and were receiving PEG-IFN treatment were enrolled. Clinical and virological parameters were monitored during 48 weeks of treatment. In addition, peripheral blood mononuclear cells (PBMCs) were collected from the 10 patients at 0, 24, and 36 weeks. RNA sequencing technology was used to analyze the RNA expression profile in the PBMC samples. Results: Following PEG-IFN treatment, we identified 217 differentially expressed genes (DEGs), most of which were upregulated. Gene ontology enrichment analysis of the DEGs revealed that they were enriched in 29 clusters, mainly associated with "antiviral defense", "innate immunity", "immunity", "defense response to virus", "response to virus", "type I interferon signaling pathway", "negative regulation of viral genome replication", "innate immune response", and "RNA-binding". Conclusion: After PEG-IFN treatment, a certain mRNA expression profile was observed in patients with CHB, providing further mechanistic insights into the antiviral effect of this therapy. Keywords: Chronic infection, Hepatitis B, PEGylated interferon, RNA sequencing Hepatitis B virus (HBV) comprises a small noncytopathic DNA virus that can infect hepatocytes and cause diverse outcomes, such as acute hepatitis B and chronic infection. The prevalence of HBV infection is defined by the positivity of serological testing of hepatitis B surface antigen (HBsAg). Areas where HBV is endemic include Asia, the Pacific islands, Africa, Southern Europe, and Latin America. 1,2 Chronic hepatitis B (CHB) virus infection impacts 296 million people around the world, being a major causative agent of hepatocellular carcinoma and cirrhosis, which lead to more than 820000 deaths annually. 3,4 Currently, the two main antiviral therapies for patients with CHB are nucleos(t)ide analogues (NA) and polyethylene glycol (PEG)ylated interferon alfa (PEG-IFNα). 5 The former includes tenofovir alafenamide (TAF), tenofovir (TDF), telbivudine (LdT), entecavir (ETV), adefovir (ADV), and lamivudine (LAM), which can inhibit viral replication and reduce the viral load. Among them, ETV, TDF, and TAF are the first-line drugs of choice because of their high antiviral potency and low resistance rates. 6 In comparison to NAs, PEG-IFNα, including PEG-IFNα-2a and α-2b, has both immune modulatory and antiviral properties. 7 For patients with CHB, PEG-IFN therapy has the benefits of a finite treatment course, a long-lasting therapeutic response, higher rates of hepatitis B e antigen (HBeAg) seroconversion, and no risk of drug resistance. However, PEG-IFN has some disadvantages, such as a moderate antiviral effect, only a subset of patients showing a sustained response, subcutaneous injection, high rates of adverse events, and high cost. 8 Furthermore, investigations into the mechanism of the effects of IFNα have revealed a clear role for IFNα treatment in antiviral activity and an immunoregulatory effect. 9 IFNα is a crucial modulator of both adaptive and innate immune responses, shaping the landscape of the immune system to coordinate various immune cells. 10 In our previous study, a certain pattern in the levels of cytokines was observed during IFNα therapy. Moreover, the early expression pattern of cytokines might be a biomarker for treatment response. 11 However, the exact mechanism remains unknown. Historically, quantitative real-time reverse transcription PCR (qRT-PCR) is used for single gene tests and is generally deemed as the "gold standard" measurement. However, it has a major limitation that only a few measurements can be made in a single assay. 12 With the evolution of deep sequencing, o -Abstract Truncated-
medicine, general & internal